Cargando…

A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management

While chronic obstructive pulmonary disease (COPD) continues to be a major cause of morbidity and mortality, pharmacological therapy has a definite benefit on symptoms as well as the frequency and severity of exacerbations, and general health. The most recent Global Initiative for Obstructive Lung D...

Descripción completa

Detalles Bibliográficos
Autores principales: Micheletto, Claudio, Braido, Fulvio, Contoli, Marco, Di Marco, Fabiano, Santus, Pierachille
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765263/
https://www.ncbi.nlm.nih.gov/pubmed/31576115
http://dx.doi.org/10.2147/COPD.S216059
_version_ 1783454529201635328
author Micheletto, Claudio
Braido, Fulvio
Contoli, Marco
Di Marco, Fabiano
Santus, Pierachille
author_facet Micheletto, Claudio
Braido, Fulvio
Contoli, Marco
Di Marco, Fabiano
Santus, Pierachille
author_sort Micheletto, Claudio
collection PubMed
description While chronic obstructive pulmonary disease (COPD) continues to be a major cause of morbidity and mortality, pharmacological therapy has a definite benefit on symptoms as well as the frequency and severity of exacerbations, and general health. The most recent Global Initiative for Obstructive Lung Disease (GOLD) guidelines recommend triple therapy (long-acting beta2 agonists [LABA] + long-acting muscarinic antagonists [LAMA] + inhaled corticosteroids [ICS]) only for patients with exacerbations, elevated eosinophils, and without control using a LABA/LAMA or ICS/LABA combination. Long-term monotherapy with ICS is not currently recommended, but may be considered in association with LABAs in patients with a history of exacerbations and elevated eosinophils in spite of appropriate treatment with long-acting bronchodilators. However, long-term use of ICS in combination therapy has been associated with adverse effects, even if widely used in routine management for decades. The available evidence suggests that ICS can be rationally discontinued in patients with stable disease and is not likely to have unfavorable effects on lung function, overall health, or be associated with a greater risk of exacerbations. Indeed, it is widely accepted that ICS therapy should be limited to a small proportion of patients after careful assessment of the individual risk-benefit profile. Unfortunately, however, there are no international recommendations that provide specific guidance or a protocol for withdrawal of ICS. Herein, the available evidence on the use of ICS is reviewed and an easy to use tool is proposed that can provide clinicians with a simple management scheme to guide the most appropriate therapy for management of COPD and use of ICS. In management of COPD, a highly personalized approach is advocated so that the most appropriate therapy for each individual patient can be selected.
format Online
Article
Text
id pubmed-6765263
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67652632019-10-01 A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management Micheletto, Claudio Braido, Fulvio Contoli, Marco Di Marco, Fabiano Santus, Pierachille Int J Chron Obstruct Pulmon Dis Review While chronic obstructive pulmonary disease (COPD) continues to be a major cause of morbidity and mortality, pharmacological therapy has a definite benefit on symptoms as well as the frequency and severity of exacerbations, and general health. The most recent Global Initiative for Obstructive Lung Disease (GOLD) guidelines recommend triple therapy (long-acting beta2 agonists [LABA] + long-acting muscarinic antagonists [LAMA] + inhaled corticosteroids [ICS]) only for patients with exacerbations, elevated eosinophils, and without control using a LABA/LAMA or ICS/LABA combination. Long-term monotherapy with ICS is not currently recommended, but may be considered in association with LABAs in patients with a history of exacerbations and elevated eosinophils in spite of appropriate treatment with long-acting bronchodilators. However, long-term use of ICS in combination therapy has been associated with adverse effects, even if widely used in routine management for decades. The available evidence suggests that ICS can be rationally discontinued in patients with stable disease and is not likely to have unfavorable effects on lung function, overall health, or be associated with a greater risk of exacerbations. Indeed, it is widely accepted that ICS therapy should be limited to a small proportion of patients after careful assessment of the individual risk-benefit profile. Unfortunately, however, there are no international recommendations that provide specific guidance or a protocol for withdrawal of ICS. Herein, the available evidence on the use of ICS is reviewed and an easy to use tool is proposed that can provide clinicians with a simple management scheme to guide the most appropriate therapy for management of COPD and use of ICS. In management of COPD, a highly personalized approach is advocated so that the most appropriate therapy for each individual patient can be selected. Dove 2019-09-23 /pmc/articles/PMC6765263/ /pubmed/31576115 http://dx.doi.org/10.2147/COPD.S216059 Text en © 2019 Micheletto et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Micheletto, Claudio
Braido, Fulvio
Contoli, Marco
Di Marco, Fabiano
Santus, Pierachille
A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
title A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
title_full A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
title_fullStr A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
title_full_unstemmed A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
title_short A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management
title_sort framework for step down or therapeutic re-organization for withdrawal of inhaled corticosteroids in selected patients with copd: a proposal for copd management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765263/
https://www.ncbi.nlm.nih.gov/pubmed/31576115
http://dx.doi.org/10.2147/COPD.S216059
work_keys_str_mv AT michelettoclaudio aframeworkforstepdownortherapeuticreorganizationforwithdrawalofinhaledcorticosteroidsinselectedpatientswithcopdaproposalforcopdmanagement
AT braidofulvio aframeworkforstepdownortherapeuticreorganizationforwithdrawalofinhaledcorticosteroidsinselectedpatientswithcopdaproposalforcopdmanagement
AT contolimarco aframeworkforstepdownortherapeuticreorganizationforwithdrawalofinhaledcorticosteroidsinselectedpatientswithcopdaproposalforcopdmanagement
AT dimarcofabiano aframeworkforstepdownortherapeuticreorganizationforwithdrawalofinhaledcorticosteroidsinselectedpatientswithcopdaproposalforcopdmanagement
AT santuspierachille aframeworkforstepdownortherapeuticreorganizationforwithdrawalofinhaledcorticosteroidsinselectedpatientswithcopdaproposalforcopdmanagement
AT michelettoclaudio frameworkforstepdownortherapeuticreorganizationforwithdrawalofinhaledcorticosteroidsinselectedpatientswithcopdaproposalforcopdmanagement
AT braidofulvio frameworkforstepdownortherapeuticreorganizationforwithdrawalofinhaledcorticosteroidsinselectedpatientswithcopdaproposalforcopdmanagement
AT contolimarco frameworkforstepdownortherapeuticreorganizationforwithdrawalofinhaledcorticosteroidsinselectedpatientswithcopdaproposalforcopdmanagement
AT dimarcofabiano frameworkforstepdownortherapeuticreorganizationforwithdrawalofinhaledcorticosteroidsinselectedpatientswithcopdaproposalforcopdmanagement
AT santuspierachille frameworkforstepdownortherapeuticreorganizationforwithdrawalofinhaledcorticosteroidsinselectedpatientswithcopdaproposalforcopdmanagement